CHMP Grants Positive Opinion to Vertex for KALYDECO® in Treating Cystic Fibrosis in Infants Aged 1 Month and Above
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion regarding the expansion of the label for KALYDECO® (ivacaftor) to include the treatment…